Skip to main content

Reference Materials Used for Specific Safety Evaluation of Human Immunoglobulin and Human Albumin Products: Features of Development, Certification and Application

  • Conference paper
  • First Online:
Reference Materials in Measurement and Technology (RMMT 2018)

Abstract

Human immunoglobulin and human albumin products can negatively affect patients’ health. The residual content of haemagglutinins, anti-D antibodies, prekallikrein activator, as well as the level of anticomplementary activity, are controlled during both production and testing for compliance with normative documentation. Methods for their quantitative evaluation are based on the effects of erythrocytes hemolysis or agglutination and on the amidolytic product properties of cascade reactions. These methods require the obligatory use of reference materials (RMs). The development of RMs, acting as the carrier of the quantitative characteristics of the human immunoglobulins and human albumin impurities, is fraught with the difficulty of selecting a candidate, substantiating the certification methodology and determining the relevant characteristics. In this research, we used human immunoglobulin solutions with normalized haemagglutinin content, anti-D antibodies or anti-complementary activity in a different range, whose quality was studied using haemagglutination and chromogenic methods and the complement fixation test. Methodological approaches to the RM development and certification were justified using system analysis and forensic audit methods. The necessity of using RMs to assess the stability of analytical work by applying anti-complementary activity determination, haemagglutinin content or anti-D antibody methods is demonstrated. It is established that RMs allow the quantitative content of haemagglutinins, anti-D antibodies and prekallikrein activator to be established. The value of the CRM characteristics should be approximated to the qualitative composition of these impurities in the analysed products, but in amounts not detectable (to produce negative RM components) or exceeding permissible maxima (to produce positive RM components).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACA:

Anticomplementary activity

PKA:

Prekallikrein activator

HA:

Human albumin

BRP:

Biological reference preparation

WHO:

World Health Organisation

HAE:

Haemagglutinins

SPh RF:

State Pharmacopoeia of the Russian Federation

Ph.Eur.:

European Pharmacopoeia

HIG:

Human immunoglobulins

IU:

International units

IHA test:

Indirect haemagglutination test

DHA test:

Direct haemagglutination test

PSF:

Product specification file

NIBSC:

National Institute for Biological Standards and Control

IRM:

Industry reference material

GM:

General monograph

CFT:

Complement fixation test

RM:

Reference material

References

  1. Volkova RA et al (2016) Topical issues related to reference standards in the sphere of circulation of biological products. BIOpreparations Preven Diagn Treat 16(4):229–236. https://doi.org/10.30895/2221-996x-2016-16-4-229-236 (In Russ)

    Article  Google Scholar 

  2. GOST ISO Guide 34-2014 (2016) General requirements for the competence of reference material producers. Standartinform Publication, Moscow (In Russ)

    Google Scholar 

  3. Ph. Eur. Reference standards. Available via https://www.edqm.eu

  4. European Pharmacopoeia EDQM, 9th edn. Subscription required. Available via http://online6.edqm.eu/ep805/#

  5. National Institute for Biological Standards and Control. Biological reference materials. Available via https://nibsc.org/products.aspx

  6. Food and Drug Administration [site]. Available via https://www.fda.gov/default.htm

  7. State Pharmacopoeia of the Russian Federation, XIII edn. Available via http://pharmacopoeia.ru/russian-pharmacopoeia

  8. WHO Technical Report Series 897 (2000). Geneva: WHO expert committee on biological standardization. Available via https://apps.who.int/iris/bitstream/handle/10665/42340/WHO_TRS_897.pdf?sequence=1

  9. Borg AL (2009) Investigation of method for determination of anticomplementary activity (ACA) in Octagam®: master’s thesis. Stockholm. Available via http://liu.diva-portal.org/smash/get/diva2:241409/fulltext01.pdf

  10. Krivykh MA, Kornilova OG, Kudasheva EY (2015) A method for obtaining a positive control of an RM of human immunoglobulin to determine the anti-complementary activity of human immunoglobulin preparations, and an RM of human immunoglobulin to determine the anti-complementary activity of human immunoglobulin preparation. RF Patent, 2577703 C1, 9 Feb 2015 (In Russ)

    Google Scholar 

  11. Krivykh MA et al (2015) Development of a reference standard for the determination of anticomplementary activity of human immunoglobulin. Khimiko-Farmatsevticheskii Zhurnal 49(6):40–42. https://doi.org/10.30906/0023-1134-2015-49-6-40-42 (In Russ)

    Article  Google Scholar 

  12. Krivykh MA et al (2016) Certification of standard samples of human immunoglobulin for determination of anticomplementary activity. Khimiko-Farmatsevticheskii Zhurnal 50(12):61–64. https://doi.org/10.30906/0023-1134-2016-50-12-61-64 (In Russ)

    Article  Google Scholar 

  13. Kornilova OG et al (2017) Contemplation of the possibility of extending the shelf life of human immunoglobulin reference standard used for determination of anticomplementary activity. BIOpreparations Prev Diagn Treat 17(2):110–115. https://doi.org/10.30895/2221-996x-2017-17-2-110-115 (In Russ)

    Article  Google Scholar 

  14. Sandberg E, Daas A, Behr-Gross M-E (2006) Collaborative study to establish human immunoglobulin BRP Batch 3 and human immunoglobulin (molecular size) BRP batch 1. Pharmeuropa Bio 1:37–49

    Google Scholar 

  15. Kornilova OG, Kudasheva EIu, Nechaev AV, Borisevich IV (2017) Reference material of anti-A and anti-B haemagglutination content in human blood preparations. RF Patent, 2017119536 (In Russ)

    Google Scholar 

  16. Kornilova OG, Nechaev AV, Borisevich IV, Kudasheva EYu (2017) Standardization of the method for determining haemagglutination content in human immunoglobulin preparations in Russia. Khim-Farm Zh 55(11):57–60. https://doi.org/10.30906/0023-1134-2017-51-11-57-60

    Article  Google Scholar 

  17. Pisani G, Wirz M, Gentili G (1996) Anti-D testing in intravenous immunoglobulins: shouldn’t it be considered? Vox Sang 71:132

    Article  CAS  Google Scholar 

  18. Turner CE, Thorpe S, Brasher M (1999) Anti–Rh D activity of commercial intravenous immunoglobulin preparations. Vox Sang 76:55–58

    Article  CAS  Google Scholar 

  19. Kornilova OG, Kudasheva EIu, Nechaev AV, Struchkova IN, Borisevich IV (2017) Reference material of anti-D antibody content in human immunoglobulin preparations. RF Patent application â„– 2017144239 (In Russ)

    Google Scholar 

  20. Krivykh MA, Kornilova OG, Zhuk IE (2017) Prekallikrein activator content in domestically-produced human albumin products. Medical Immunology 19(S):271–272 (In Russ)

    Google Scholar 

  21. Tomilin MV, Filatova EV, Kuznetsova MM, Sudakova VV, Zubkova NV (2017) Validation of the method for determination of prekallikrein activator in Human Albumin. BIOpreparations Prev Diagn Treat 17(1):59–64. https://doi.org/10.30895/2221-996x-2017-17-1-59-64 (In Russ)

    Article  Google Scholar 

Download references

Acknowledgements

The authors sincerely thank the reviewers and the Editorial board for the highly professional and benevolent attitude during the preparation of materials for publication.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Olga G. Kornilova .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this paper

Check for updates. Verify currency and authenticity via CrossMark

Cite this paper

Kornilova, O.G., Krivykh, M.A., Volkova, R.A., Borisevich, I.V. (2020). Reference Materials Used for Specific Safety Evaluation of Human Immunoglobulin and Human Albumin Products: Features of Development, Certification and Application. In: Medvedevskikh, S., Kremleva, O., Vasil’eva, I., Sobina, E. (eds) Reference Materials in Measurement and Technology. RMMT 2018. Springer, Cham. https://doi.org/10.1007/978-3-030-32534-3_5

Download citation

Publish with us

Policies and ethics